Abstract 13640: Dapagliflozin Lowers HbA1c, Systolic Blood Pressure and Serum Uric Acid in Patients With Type 2 Diabetes and Hypertension, Regardless of Class of Concomitant Antihypertensive Therapy
| Autor: | Agata Ptaszynska, Shamik Parikh, Michael A. Weber, Nayyar Iqbal, Traci A Mansfield |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry Urology Type 2 diabetes Placebo medicine.disease Excretion chemistry.chemical_compound Blood pressure Endocrinology chemistry Weight loss Physiology (medical) Concomitant Internal medicine Medicine medicine.symptom Dapagliflozin Cardiology and Cardiovascular Medicine business Thiazide medicine.drug |
| Zdroj: | Circulation. 130 |
| ISSN: | 1524-4539 0009-7322 |
| Popis: | Hypertension (HTN) in Type 2 diabetes (T2D) is often treated with an ACEi/ARB + additional antihypertensives agents (AHTs). Dapagliflozin (DAPA) is an inhibitor of sodium glucose co-transporter 2, reducing hyperglycemia in T2D by increasing urinary glucose excretion. This is associated with weight reduction, osmotic diuresis and serum uric acid reduction, all of which may contribute to BP lowering. This Phase 3 study assessed 12 weeks of DAPA 10 mg (N=225) or placebo (PBO; N=224) in T2D patients (HbA1c 7.0-10.5%) with HTN (seated SBP / DBP 140 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|